2019
LPTO-10. ASSESSMENT OF LEPTOMENINGEAL CARCINOMATOSIS DIAGNOSIS AND OUTCOMES FROM 2005 TO 2015 AT THE OHIO STATE UNIVERSITY
Williams N, Rinehardt H, Morgan E, Kassem M, Palettas M, Puduvalli V, Giglo P, Lustberg M, Wesolowski R, Sardesai S, Stover D, Vandeusen J, Bazan J, Ramaswamy B, Noonan A. LPTO-10. ASSESSMENT OF LEPTOMENINGEAL CARCINOMATOSIS DIAGNOSIS AND OUTCOMES FROM 2005 TO 2015 AT THE OHIO STATE UNIVERSITY. Neuro-Oncology Advances 2019, 1: i8-i8. PMCID: PMC7213376, DOI: 10.1093/noajnl/vdz014.033.Peer-Reviewed Original ResearchDiagnosis of LCMagnetic resonance imagingLeptomeningeal carcinomatosisLMC diagnosisOverall survivalPrimary cancerOhio State University Comprehensive Cancer CenterSingle-institution retrospective studyCentral nervous system malignanciesMedian overall survivalStage II diseaseStage III diseaseStage IV diseaseKaplan-Meier methodPrimary breast cancerSurvival of patientsNervous system malignanciesCerebrospinal fluid cytologySolid tumor malignanciesConfirmation of diagnosisComprehensive cancer centerClinical characteristicsMedian ageMRI findingsInitial diagnosisAssessment of Leptomeningeal Carcinomatosis Diagnosis and Outcomes from 2005 to 2015 at Ohio State University.
Rinehardt H, Morgan E, Kassem M, Palettas M, Miah A, Alnahhas I, Guillermo Prieto Eibl P, Suresh A, Ganju A, Williams N, Puduvalli V, Giglio P, Lustberg M, Wesolowski R, Sardesai S, Stover D, Vandeusen J, Bazan J, Ramaswamy B, Noonan A. Assessment of Leptomeningeal Carcinomatosis Diagnosis and Outcomes from 2005 to 2015 at Ohio State University. Journal Of Clinical Oncology 2019, 37: e13554-e13554. DOI: 10.1200/jco.2019.37.15_suppl.e13554.Peer-Reviewed Original ResearchDiagnosis of LCMagnetic resonance imagingLeptomeningeal carcinomatosisLMC diagnosisOverall survivalMRI findingsPrimary cancerLung cancerBreast cancerOhio State University Comprehensive Cancer CenterStage IV breast cancerSingle-institution retrospective studyCentral nervous system malignanciesMedian overall survivalStage II diseaseStage III diseaseStage IV diseaseHigh-risk patientsKaplan-Meier methodPrimary breast cancerSurvival of patientsNervous system malignanciesCerebrospinal fluid cytologyConfirmation of diagnosisComprehensive cancer center
2010
Phase II trial of neoadjuvant chemotherapy (NCT) with weekly nanoparticle albumin-bound paclitaxel (Nab-P), carboplatin (CBP), and bevacizumab (BEV) in women with clinical stages II-III breast cancer (BC): Pathologic response prediction by changes in angiogenic volume (AV) by dynamic contrast magnetic resonance imaging (DCE-MRI).
Mrozek E, Lustberg M, Knopp M, Spigos D, Yang X, Houton L, Ramaswamy B, Layman R, Povoski S, Agnese D. Phase II trial of neoadjuvant chemotherapy (NCT) with weekly nanoparticle albumin-bound paclitaxel (Nab-P), carboplatin (CBP), and bevacizumab (BEV) in women with clinical stages II-III breast cancer (BC): Pathologic response prediction by changes in angiogenic volume (AV) by dynamic contrast magnetic resonance imaging (DCE-MRI). Journal Of Clinical Oncology 2010, 28: 604-604. DOI: 10.1200/jco.2010.28.15_suppl.604.Peer-Reviewed Original ResearchNeoadjuvant chemotherapyBreast cancerDynamic contrast magnetic resonance imagingWeekly nanoparticle albumin-bound paclitaxelNanoparticle albumin-bound paclitaxelClinical stage IIPhase II trialAlbumin-bound paclitaxelContrast magnetic resonance imagingMagnetic resonance imagingII trialResonance imagingStage IIBevacizumabCarboplatinChemotherapyCancerPaclitaxelTrials